|
|
|
|
Spectral granted IDE approval by U.S. FDA to conduct pivotal trial for Toraymyxin
- Spectral Diagnostics Inc.announced that the U.S. Food and Drug Administration (FDA) has granted Investigational Device Exemption (IDE) approval for Toraymyxin(TM), a therapeutic hemoperfusion device that removes endotoxin from the bloodstream, allowing...
|
|
|
BioMS Medical reports Spectral receives FDA approval to initiate pivotal trial and closes financing for $19.5
EDMONTON, March 3 /PRNewswire-FirstCall/ - BioMS Medical Corp.(TSX: MS) today reported that Spectral Diagnostics (TSX: SDI) has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) for Toraymyxin(TM).
|
|
|
BioMS Medical reports Spectral receives FDA approval to initiate pivotal trial and closes financing for $19.5
Toronto Stock Exchange Symbol: MS EDMONTON, March 3 /CNW/ - BioMS Medical Corp.(TSX: MS) today reported that Spectral Diagnostics (TSX: SDI) has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) for...
|
|
|
3/3/10 - BioMS Medical reports Spectral receives FDA approval to initiate pivotal trial and closes financing f
EDMONTON, March 3 /PRNewswire-FirstCall/ - BioMS Medical Corp.(TSX: MS) today reported that Spectral Diagnostics (TSX: SDI) has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) for Toraymyxin(TM).
|
|
|
BioMS Medical reports Spectral receives FDA approval to initiate pivotal trial and closes financing for $19.5
EDMONTON, March 3 /PRNewswire-FirstCall/ - BioMS Medical Corp.(TSX: MS) today reported that Spectral Diagnostics (TSX: SDI) has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) for Toraymyxin(TM).
|
|
|
Spectral granted IDE approval by U.S. FDA to conduct pivotal trial for Toraymyxin(TM)
TORONTO, March 2 /PRNewswire-FirstCall/ - Spectral Diagnostics Inc.(TSX:SDI), a company developing products for the treatment of sepsis, today announced that the U.S. Food and Drug Administration (FDA) has granted Investigational Device Exemption (IDE)...
|
|
|
Spectral granted IDE approval by U.S. FDA to conduct pivotal trial for Toraymyxin(TM)
TORONTO, March 2 /PRNewswire-FirstCall/ - Spectral Diagnostics Inc.(TSX:SDI), a company developing products for the treatment of sepsis, today announced that the U.S. Food and Drug Administration (FDA) has granted Investigational Device Exemption (IDE)...
|
|
|
BioMS Medical reports Spectral receives FDA approval to initiate pivotal trial and closes financing for $19.5
EDMONTON, March 3 /PRNewswire-FirstCall/ - BioMS Medical Corp.(TSX: MS) today reported that Spectral Diagnostics (TSX: SDI) has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) for Toraymyxin(TM).
|
|
|
BioMS Medical reports Spectral receives FDA approval to initiate pivotal trial and closes financing for $19.5 million
BioMS Medical reports Spectral receives FDA approval to initiate pivotal trial and closes financing for $19.5 million Toronto Stock Exchange Symbol: MS EDMONTON, March 3 /CNW/ - BioMS Medical Corp.(TSX: MS) today reported that Spectral Diagnostics (TSX: SDI)...
|
|
|
BioMS Medical reports Spectral receives FDA approval to initiate pivotal trial and closes financing for $19.5 million
BioMS Medical Corp.(TSX: MS) today reported that Spectral Diagnostics (TSX: SDI) has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) for Toraymyxin(TM). Spectral Diagnostics and BioMS have entered...
|
|
|
BioMS Medical reports Spectral receives FDA approval to initiate pivotal trial and closes financing for $19.5 million
BioMS Medical Corp.(TSX: MS) today reported that Spectral Diagnostics (TSX: SDI) has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) for Toraymyxin(TM). Spectral Diagnostics and BioMS have entered...
|
|
|
BioMS Medical reports Spectral receives FDA approval to initiate pivotal trial and closes financing for $19.5 million
BioMS Medical Corp.(TSX: MS) today reported that Spectral Diagnostics (TSX: SDI) has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) for Toraymyxin(TM). Spectral Diagnostics and BioMS have entered...
|
|
|
BioMS Medical reports Spectral receives FDA approval to initiate pivotal trial and closes financing for $19.5 million
BioMS Medical Corp.(TSX: MS) today reported that Spectral Diagnostics (TSX: SDI) has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) for Toraymyxin(TM). Spectral Diagnostics and BioMS have entered...
|
|
|
BioMS Medical reports Spectral receives FDA approval to initiate pivotal trial and closes financing for $19.5 million
Toronto Stock Exchange Symbol: MS Spectral also reported that it has closed its previously announced private placement of 48,750,000 units of the Company for gross proceeds of $19.5 million.BioMS subscribed to 30,000,000 of the units. The EUPHRATES ...
|
|
|
BioMS Medical reports Spectral receives FDA approval to initiate pivotal trial and closes financing for $19.5 million
BioMS Medical Corp.(TSX: MS) today reported that Spectral Diagnostics (TSX: SDI) has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) for Toraymyxin(TM). Spectral Diagnostics and BioMS have entered...
|
|
|
BioMS Medical reports Spectral receives FDA approval to initiate pivotal trial and closes financing for $19.5 million
Toronto Stock Exchange Symbol: MS Spectral also reported that it has closed its previously announced private placement of 48,750,000 units of the Company for gross proceeds of $19.5 million.BioMS subscribed to 30,000,000 of the units. The EUPHRATES ...
|
|
|
BioMS Medical reports Spectral receives FDA approval to initiate pivotal trial and closes financing for $19.5 million
BioMS Medical Corp.(TSX: MS) today reported that Spectral Diagnostics (TSX: SDI) has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) for Toraymyxin(TM). Spectral Diagnostics and BioMS have entered...
|
|
|
BioMS Medical reports Spectral receives FDA approval to initiate pivotal trial and closes financing for $19.5 million
BioMS Medical Corp.(TSX: MS) today reported that Spectral Diagnostics (TSX: SDI) has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) for Toraymyxin(TM). Spectral Diagnostics and BioMS have entered...
|
|
|
BioMS Medical reports Spectral receives FDA approval to initiate pivotal trial and closes financing for $19.5 million
BioMS Medical Corp.(TSX: MS) today reported that Spectral Diagnostics (TSX: SDI) has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) for Toraymyxin(TM). Spectral Diagnostics and BioMS have entered...
|
|
|
BioMS Medical reports Spectral receives FDA approval to initiate pivotal trial and closes financing for $19.5 million
BioMS Medical Corp.(TSX: MS) today reported that Spectral Diagnostics (TSX: SDI) has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) for Toraymyxin(TM). Spectral Diagnostics and BioMS have entered...
|
|
|
BioMS Medical reports Spectral receives FDA approval to initiate pivotal trial and closes financing for $19.5 million
BioMS Medical Corp.(TSX: MS) today reported that Spectral Diagnostics (TSX: SDI) has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) for Toraymyxin(TM). Spectral Diagnostics and BioMS have entered...
|
|
|
Spectral Diagnostics receives FDA IDE approval for Toraymyxin
BioMS Medical Corp.(TSX: MS) today reported that Spectral Diagnostics (TSX: SDI) has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) for Toraymyxin(TM). Spectral Diagnostics and BioMS have entered...
|
|
|
BioMS Medical reports Spectral receives FDA approval to initiate pivotal trial and closes financing for $19.5 million
BioMS Medical reports Spectral receives FDA approval to initiate pivotal trial and closes financing for $19.5 million Toronto Stock Exchange Symbol: MS EDMONTON, March 3 /CNW/ - BioMS Medical Corp.(TSX: MS) today reported that Spectral Diagnostics (TSX: SDI)...
|
|
|
BioMS Medical reports Spectral receives FDA approval to initiate pivotal trial and closes financing
Toronto Stock Exchange Symbol: MS EDMONTON, March 3 /PRNewswire-FirstCall/ - BioMS Medical Corp.Spectral also reported that it has closed its previously announced private placement of 48,750,000 units of the Company for gross proceeds of $19.5 million.
|
|
|
BioMS Medical reports Spectral receives FDA approval to initiate pivotal trial and closes financing for $19.5
Toronto Stock Exchange Symbol: MS EDMONTON, March 3 /PRNewswire-FirstCall/ - BioMS Medical Corp.(TSX:MS) today reported that Spectral Diagnostics (TSX:SDI) has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug...
|
